Guidelines on themanagement of arterial hypertension and related comorbidities in Latin America

dc.contributor.authorBurlando, Guillermo
dc.contributor.authorGonzalez, Claudio
dc.contributor.authorPiskorz, Daniel
dc.contributor.authorRamirez, Agustín J.
dc.contributor.authorSanchez, Ramiro A.
dc.contributor.authorSimsolo, Rosa
dc.contributor.authorVoto, Liliana
dc.contributor.authorAlessi, Alexandre
dc.contributor.authorAmodeo, Celso
dc.contributor.authorAraujo Brandáo, Andrea
dc.contributor.authorBaiocchi, Sergio
dc.contributor.authorBarbosa, Eduardo
dc.contributor.authorBarreto Filho, José Augusto
dc.contributor.authorBrandaó Veiga, Paulo César
dc.contributor.authorBrasil, David
dc.contributor.authorDischinger Miranda, Roberto
dc.contributor.authorFritsch, Mario
dc.contributor.authorKalil, Marcio
dc.contributor.authorMachado, Carlos Alberto
dc.contributor.authorMagalhaés Feitosa, Audes
dc.contributor.authorBolivar Malachias, Marcus Vinicius
dc.contributor.authorMalta, Deborah
dc.contributor.authorDecio Mion, Jr.
dc.contributor.authorMoreno, Heitor
dc.contributor.authorMota Gomes, Marco
dc.contributor.authorNobre, Fernando
dc.contributor.authorNogueira, Armando
dc.contributor.authorOigman, Wille
dc.contributor.authorPassarelli Jr., Oswaldo
dc.contributor.authorRibeiro, José Márcio
dc.contributor.authorSantos Póvoa, Rui Manoel
dc.contributor.authorSchmid, Helena
dc.contributor.authorSebba Barroso, Weimar Kunz
dc.contributor.authorVeiga Jardim, Thiago
dc.contributor.authorVilela-Martin, José Fernando
dc.contributor.authorCobos, Leonardo
dc.contributor.authorLanas, Fernando
dc.contributor.authorVillar Moya, Raul
dc.contributor.authorAccini Mendoza, José Luis
dc.contributor.authorGarcia-Ortiz, Luis Hernando
dc.contributor.authorLópez-Jaramillo, Patricio
dc.contributor.authorMolina, Dora Ines
dc.contributor.authorSanchez, Gregorio
dc.contributor.authorUrina – Triana, Miguel
dc.contributor.authorMorales-Salinas, Alberto
dc.contributor.authorLara, Joffre
dc.contributor.authorStuardo Wyss, Fernando
dc.contributor.authorAlcocer, Luis
dc.contributor.authorGonzalez Caamanó, Angel
dc.contributor.authorParra-Carrillo, Jose Z.
dc.contributor.authorOrtellado, José
dc.contributor.authorBryce Moncloa, Alfonso
dc.contributor.authorSenclen Santisteban, Segundo
dc.contributor.authorDiaz, Margarita E.
dc.contributor.authorHernandez Hernandez, Rafael
dc.contributor.authorLopez, Jesús
dc.contributor.authorMachado, Livia T.
dc.contributor.authorPonte-Negretti, Carlos
dc.description.abstractABI, ankle-brachial index; ABPM, ambulatory blood pressure monitoring; ACCORD, Action to Control Cardiovascular Risk in Diabetes; ACE-I, angiotensin-converting-enzyme-inhibitors; ARB, AT1 blockers; BP, blood pressure; CARMELA, Cardiovascular Risk Factor Multiple Evaluation in Latin America; CARMEN, Community Actions for Multifactorial Reduction of Non- Communicable Diseases; CCB, calcium channel blocker; CCM, Wagner’s Chronic Care Model; CDC, Chronic Disease Center; CTA, computed tomography angiography; CV, cardiovascular; DALY, disability-adjusted life year; DPP- 4, dipeptidyl-peptidase-4; GLP-1, glucagon-like peptide 1; HBPM, home blood pressure monitoring; HOPE, Heart Outcomes Prevention Evaluation; HOT, Hypertension Optimal Treatment; HT, hypertension; LA, Latin America; LASH, Latin American Society of Hypertension; MRA, magnetic resonance angiography; NCD, noncommunicable disease; OSAS, obstructive apnea–hypopnea syndrome; PAD, peripheral artery disease; PAHO, Pan American Health Organization; RAAS, renin–angiotensin–aldosterone system; RISS, Redes Integradas de Servicios de Salud; SGLUT2, sodium–glucose cotransporter-2; SPRINT, SBP Intervention Trial; UKPDS, United Kingdom Prospective Diabetes Study; VIDA, Veracruz Initiative for Diabetes Awarenessspa
dc.publisherInternational Society of Hypertensioneng
dc.rights.licenseLicencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacionalspa
dc.sourceJournal of Hypertensioneng
dc.sourceVol. 35, No.8 (2017)eng
dc.subjectLatin Americaeng
dc.titleGuidelines on themanagement of arterial hypertension and related comorbidities in Latin Americaeng
dc.title.alternativeTask Force of the Latin American Society of Hypertensioneng
dcterms.referencesForouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, et al., GBD 2013 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386:2287–323.eng
dcterms.referencesWorld Health Organization. Global status report on noncommunicable diseases 2010. Geneva: World Health Organization; 2011.eng
dcterms.referencesLewington S, Clarke R, Qizilbash N, Peto R, Collins R, for the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903–1913.eng
dcterms.referencesLopez-Jaramillo P, Molina de Salazar DI, Coca A, Zanchetti A. Manual Práctico LASH de Diagnóstico y Manejo de la Hipertensio´n Arterial en Latinoame´rica. 2013;
dcterms.referencesDíaz ME. Prevalence of hypertension in Latin America. In: Hernandez RH, Armas-Hernandez MJ, editors. Current advances in hypertension. Proceedings of the IV Latin American Congress on Hypertension – Latin American Society of Hypertension. Bologna: Medimond; 2005. pp. 1–8.eng
dcterms.referencesColeman K, Austin BT, Brach C, Wagner EH. Evidence on the chronic care model. The new millennium. Health Aff 2009; 28:75–85.eng
dcterms.referencesMengue SS, Bertoldi AD, Ramos LR, Farias MR, Oliveira MA, Tavares NU, et al. Acesso e uso de medicamentos para hipertensaó arterial no Brasil. Rev Saude Publica 2016; 50 (Suppl 2):1s–9s.eng
dcterms.referencesOliveira Araujo JL, Pereira MD, Del Fiol FS, Barberato-Filho S. Access to antihypertensive agents in Brazil: evaluation of the ‘Health Has No Price’ program. Clin Ther 2014; 36:1191–1195.eng
dcterms.referencesHernández-Hernández R, Silva H, Velasco M, Pellegrini F, Macchia A, Escobedo J, et al. Hypertension in seven Latin American cities: the Cardiovascular Risk Factor MultipleEvaluation in Latin America (CARMELA) study. J Hypertens 2010; 28:24–34.eng
dcterms.referencesSchargrodsky H, Hernández-Hernández R, Champagne BM, Silva H, Vinueza R, Silva Ayc¸aguer LC, et al., CARMELA Study Investigators. CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am J Med 2008; 121:58–65.eng
dcterms.referencesTeo K, Chow CK, Vaz M, Rangarajan S, Yusuf S, PURE Investigators- Writing Group. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J 2009; 158:1–7.eng
dcterms.referencesChow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al., PURE (Prospective Urban Rural Epidemiology) Study Investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310:959–968.eng
dcterms.referencesD’Agostino RB, Vasan RS Sr, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743–753.eng
dcterms.referencesConroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al., SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart 2003; 24:987–1003.eng
dcterms.referencesBryce-Moncloa A, Lara J, Cobos L, San-Martín M, et al.: Consenso para el control del riesgo cardiovascular en el Pacífico Sur (Ecuador, Peru´ y Chile). Colegio Panamericano de Endotelio, 2015, pg.: 16–27. Impreso en: IMPRESSO GRAFICA, Miraflores, Lima, Perú . Hecho el depósito legal en la Biblioteca Nacional del Peru´:N- 2015- 16031.eng
dcterms.referencesLopez Jaramillo P, Sanchez RA, Diaz M, Cobos L, Bryce A, Parra- Carrillo JZ, et al. Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome. J Hypertens 2013; 31:223–238.eng
dcterms.referencesStahl CH, Lind M, Svensson AM, Gudbjörnsdottir S, Ma°rtensson A, Rosengren A. Glycemic control and excess risk of ischemic and hemorrhagic stroke in patients with type 1 diabetes: a cohort study of 33 453 patients. J Intern Med 2016; doi:10.1111/joim.12572.eng
dcterms.referencesAlegre Diaz J, Harrington W, Lopez-Cervantes M, Gnatiuc L. Diabetes and cause-specific mortality in Mexico City. N Engl J Med 2016; 17:1961–1971.eng
dcterms.referencesPatel YR, Kirkman MS, Considine RV, Hannon TS, Mather KJ. Retinopathy predicts progression of fasting plasma glucose: an Early Diabetes Intervention Program (EDIP) analysis. Exp Clin Endocrinol Diabetes 2016; doi:10.1055/s-0042-117717.eng
dcterms.referencesVrsalovic M, Vucur K, Vrsalovic Presecki A, Fabijanic D, Milosevic M. Impact of diabetes on mortality in peripheral artery disease: a metaanalysis. Clin Cardiol 2016; [Epub ahead of print].eng
dcterms.referencesGandhi J, Dagur G, Warren K, Smith N, Khan SA. The role of sexual dysfunction and infertility on reproductive health in diabetics: pathogenesis, evaluation, and management. Curr Diabetes Rev 2016; [Epub ahead of print].eng
dcterms.referencesKhalil H. Diabetes microvascular complications – a clinical update. Diabetes Metab Syndr 2016; [Epub ahead of print].eng
dcterms.referencesRamalingam L, Menikdiwela K, LeMieux M, Dufour JM, Kaur G, Kalupahana N, Moustaid-Moussa N. The renin angiotensin system, oxidative stress and mitochondrial function in obesity and insulin resistance. Biochem Biophys Acta 2016; [Epub ahead of print].eng
dcterms.referencesHolwerda SW, Vianna LC, Restaino RM, Chaudhary K, Young CN, Fadel PJ. Arterial baroreflex control of sympathetic nerve activity and heart rate in patients with type 2 diabetes. Am J Physiol Heart Circ Physiol 2016; 311:H1170–H1179.eng
dcterms.referencesGupta S, Wang Z. Predictors of sleep disorders among patients with type 2 diabetes mellitus. Diabetes Metab Syndr 2016; 10:213–220.eng
dcterms.referencesDePace NL, Mears JP, Yayac M, Colombo J. Cardiac autonomic testing and diagnosing heart disease. ‘A clinical perspective’. Heart Int 2014; 9:37–44.eng
dcterms.referencesSingh JP, Larson MG, O’Donnell CJ, Wilson PF, Tsuji H, Lloyd-Jones DM, Levy D. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). Am J Cardiol 2000; 86:309–312.eng
dcterms.referencesSempertegui F, Estrella B, Tucker KL, Hamer DH, Narvaez X, Sempertegui M, et al. Metabolic syndrome in the elderly living in marginal peri-urban communities in Quito, Ecuador. Public Health Nutr 2011; 14:758–767.eng
dcterms.referencesAlvarez C, Salazar R, Galindez J, Rangel F, Castan˜eda ML, Lopardo G, et al. Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America. Braz J Infect Dis 2010; 14:256–263.eng
dcterms.referencesBermudez V, Marcano RP, Cano C, Arraı´z N, Amell A, Cabrera M, et al. The Maracaibo city metabolic syndrome prevalence study: design and scope. Am J Ther 2010; 17:288–294.eng
dcterms.referencesEscobedo J, Schargrodsky H, Champagne B, Silva H, Boissonnet CP, Vinueza R, et al. Prevalence of the metabolic syndromein LatinAmerica and its association with sub-clinical carotid atherosclerosis: the CARMELA cross sectional study. Cardiovasc Diabetol 2009; 26:8–52.eng
dcterms.referencesCaceres M, Teran CG, Rodriguez S, Medina M. Prevalence of insulin resistance and its association with metabolic syndrome criteria among Bolivian children and adolescents with obesity. BMC Pediatr 2008; 8:1–6.eng
dcterms.referencesRoyer M, Castelo-Branco C, Blumel JE, Chedraui PA, Danckers L, Bencosme A, et al., Collaborative Group for Research of the Climacteric in Latin America. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American women. Climacteric 2007; 10:164–170.eng
dcterms.referencesGarcia RG, Perez M, Maas R, Schwedhelm E, Boger RH, Lopez- Jaramillo P. Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. Int J Cardiol 2007; 122:176–178.eng
dcterms.referencesAlberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640–1645.eng
dcterms.referencesReaven GM. Insulin resistance/compensatory hyper insulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003; 88:2399–2403.eng
dcterms.referencesCarr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III Criteria for the Metabolic Syndrome. Diabetes 2004; 53:2087–2094.eng
dcterms.referencesSpence JD. Cerebral consequences of hypertension. J Hypertens 1996; 14:S139–S145.eng
dcterms.referencesO’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al., INTERSTROKE Investigators. Risk factors for ischemic and intracerebral hemorrhagic stroke in 22 countries (the INTERSTROKE study): a case–control study. Lancet 2010; 376:112–123.eng
dcterms.referencesFeigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, BennettDA, et al., Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD2010) and theGBDStroke Experts Group. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 2014; 383:245–255.eng
dcterms.referencesPorcello Marrone LC, Diogo LP, de Oliveira FM, Trentin S, Scalco RS, et al. Risk factors among stroke subtypes Brazil. J Stroke Cerebrovasc Dis 2013; 22:32–35.eng
dcterms.referencesDe Jesús Llibre J, Valhuerdi A, Fernandez O, Llibre JC, Porto R, Lopez AM, et al. Prevalence of stroke and associated risk factors in older adults in Havana city and Matanzas province, Cuba. MEDICC Rev 2010; 12:20–26.eng
dcterms.referencesLanas F, Serón P, Lanas A. Cardiovascular disease in Latin America: the growing epidemic. Progr Cardiovasc Dis 2014; 57:262–267.eng
dcterms.referencesManolio TA, Kronmal RA, Burke GL, Poirier V, O’Leary DH, Gardin JM, et al. Magnetic resonance abnormalities and cardiovascular disease in older adults: the Cardiovascular Health Study. Stroke 1994; 25:318–327.eng
dcterms.referencesYusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al., INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 2004; 364:937–952.eng
dcterms.referencesLanas F, Avezum A, Bautista LE, Diaz R, Luna M, Islam S, et al., INTERHEART Investigators in Latin America. Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. Circulation 2007; 115:1067–1074.eng
dcterms.referencesDokainish H, Teo K, Zhu J, Roy A, AlHabib KF, ElSayed A, et al., INTER-CHF Investigators. Heart failure in Africa, Asia, The middle East and South America: the INTER-CHF study. Int J Cardiol 2016; 204:133–141.eng
dcterms.referencesRodriguez CJ, Diez-Roux AV, Moran A, Jin Z, Kronmal RA, Lima J, et al. Left ventricular mass and ventricular remodelling among Hispanic subgroups compared with non-Hispanic blacks and whites MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2010; 55:234–242.eng
dcterms.referencesBocchi EA. The reality of heart failure in Latin America. J Am Coll Cardiol 2013; 62:949–958.eng
dcterms.referencesSacco RL, Boden-Albala B, Abel G, Lin IF, Elkind M, Hauser WA, et al. Race-ethnic disparities in the impact of stroke risk factors: the northern Manhattan stroke study. Stroke 2001; 32:1725–1731.eng
dcterms.referencesCowley AW Jr, Roman RJ. The role of the kidney in hypertension. JAMA 1996; 275:1581–1589.eng
dcterms.referencesTextor S. Atherosclerotic renal artery stenosis: how big is the problem and what happens if nothing is done? J Hypertens 2005; 23 (Suppl 3):s5–s13.eng
dcterms.referencesLance D, Dworkin M, Elliott WJ. Secondary hypertension: renovascular hypertension. In: Black H, Elliott WG, editors. Hypertension: a companion to Braunwald’s Heart Disease. Saunders Elsevier; 2007. pp. 93–105.eng
dcterms.referencesKrumme W, Blum U, Schwertfeger E, Flugel P, Hollstin F, Schollmeyer P, et al. Diagnosis of renovascular disease by intra- and extrarenal Doppler scanning. Kidney Int 1996; 50:1288–1292.eng
dcterms.referencesSafian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001; 344:431–442.eng
dcterms.referencesPlouin PF, Chatellier G, Darne B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. EssaiMulticentrique Medicaments vs Angioplastie (EMMA) Study Group. Hypertension 1998; 31:823–829.eng
dcterms.referencesRosa-Diez G, Gonzalez-Bedat M, Pecoits-Filho R, Marinovich S, Fernandez S, Lugon J, et al. Renal replacement therapy in Latin American end-stage renal disease. Clin Kidney J 2014; 7:431–436.eng
dcterms.referencesMurabito JM, D’Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication: a risk profile from the Framingham Heart Study. Circulation 1997; 96:44–49.eng
dcterms.referencesBertomeu V, Morillas P, Gonzalez-Juanatey JR, Quiles J, Guindo J, Soria F, et al. Prevalence and prognostic influence of peripheral arterial disease in patients 40 years old admitted into hospital following an acute coronary event. Eur J Vasc Endovasc Surg 2008; 36:189–196.eng
dcterms.referencesIngolfsson IO, Sigurdsson G, Sigvaldason H, Thorgeirsson G, Sigfusson N. A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968–1986: a strong relationship to smoking and serum cholesterol the Reykjavik Study. J Clin Epidemiol 1994; 47:1237–1243.eng
dcterms.referencesSanchez RA, Ayala M, Baglivo H, Velásquez C, Burlando G, Kohlmann O, et al., Latin America Expert Group. Latin American guidelines on hypertension. J Hypertens 2009; 27:905–922.eng
dcterms.referencesParati G, Stergiou G, O’Brien E, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension guidelines for ambulatory blood pressure monitoring. J Hypertens 2014; 32:1359–1366.eng
dcterms.referencesMancia G, Bombelli M, Seravalle G, Grassi G. Diagnosis and management of patients with white-coat and masked hypertension. Nat Rev Cardiol 2011; 8:686–693.eng
dcterms.referencesLongo D, Dorigatti F, Palatini P. Masked hypertension in adults. Blood Press Monit 2005; 10:307–310.eng
dcterms.referencesHo JE, Larson MG, Ghorbani A, Cheng S, Coglianese EE, Vasan RS, Wang TJ. Long-term cardiovascular risks associated with an elevated heart rate: the Framingham Heart Study. J Am Heart Assoc 2014; 3:e000668.eng
dcterms.referencesPalatini P, AgabitiRosei E, Casiglia E, Chalmers J, Ferrari R, Grassi G, et al. Management of the hypertensive patient with elevated heart rate: statement of the second consensus conference endorsed by the European Society of Hypertension. J Hypertens 2016; 34:813–821.eng
dcterms.referencesPickering TG, Hall JE, Appel LJ, Falkner BE, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: a statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005; 45:142–161.eng
dcterms.referencesKang YY, Li Y, Huang QF, Song J, Shan XL, Dou Y, et al. Accuracy of home versus ambulatory blood pressure monitoring in the diagnosis of white-coat and masked hypertension. J Hypertens 2015; 33:1580–1587.eng
dcterms.referencesParati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, et al., ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension Practice Guidelines for home blood pressure monitoring. J Human Hypertens 2010; 24:779–785.eng
dcterms.referencesThomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, metaanalyses and meta-regression analyses of randomized trials. J Hypertens 2014; 32:2285–2295.eng
dcterms.referencesGrotto I, Huerta M, Sharabi I. Hypertension and socio-economic status. Curr Opin Cardiol 2008; 23:335–339.eng
dcterms.referencesFlescher NL, Diez Rux AV, Alazraqui M, Spinelli H. Social patterning of chronic disease risk factors in a Latin American city. J Urban Health 2008; 85:923–937.eng
dcterms.referencesLopez-Jaramillo P, Coca A, Sanchez R, Zanchetti A. Is it time to reappraise blood pressure thresholds and targets? Position Statement of the Latin American Society of Hypertension. Hypertension 2016; 68:257–262.eng
dcterms.referencesMancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281–1357.eng
dcterms.referencesJames PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507–520.eng
dcterms.referencesNational Institute for Health and Clinical Excellence. Hypertension (CG127): clinical management of primary hypertension in adults.
dcterms.referencesWeber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32:3–15.eng
dcterms.referencesZanchetti A. Do we over treat mild hypertension? Expert Opin Pharmacother 2015; 16:1121–1126.eng
dcterms.referencesLonn EM, Bosch J, Lopez Jaramillo P, Zhu J, Liu L, Pais P, et al. Blood pressure lowering in intermediate risk persons without cardiovascular disease. N Engl J Med 2016; 374:2009–2020.eng
dcterms.referencesWright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al., The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373:2103–2116.eng
dcterms.referencesParati G, Ochoa JE, Bilo G, Zanchetti A. SPRINT blood pressure; sprinting back to Smirk’s basal blood pressure? Hypertension 2017; 69:15–19.eng
dcterms.referencesThomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 7. Effects of more versus less intensive blood pressure lowering and different achieved blood pressure levels – updated overview and meta-analyses of randomized trials. J Hypertens 2016; 34:613–622.eng
dcterms.referencesThomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs. discontinuations because of adverse drug events – meta-analyses of randomized trials. J Hypertens 2016; 34:1451–1463.eng
dcterms.referencesFagard RH. Exercise therapy in hypertensive cardiovascular disease. Prog Cardiovasc Dis 2011; 53:404–411.eng
dcterms.referencesLeong DP, Teo KK, Rangarajan S, Lopez Jaramillo P, Avezum A, Orlandini A, et al., Prospective Urban Rural Epidemiology (PURE) Study Investigators. Prognostic value of grip strength: Findings from the Prospective Urban Rural Epidemiology (PURE) Study. Lancet 2015; 836:266–273.eng
dcterms.referencesMorales Salinas A, Coca A, Olsen MH, Sanchez R, Sebba Barroso WK, Kones R, et al. Clinical perspective on antihypertensive drug treatment in adults with grade 1 hypertension and low–moderate risk: an international expert consultation. Curr Probl Cardiol 2017; [in publication].eng
dcterms.referencesThomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk-overview and meta-analyses of randomized trials. J Hypertens 2014; 32:2305–2314.eng
dcterms.referencesGupta AK, Arshad S, Poulter NR. Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive agents: a metaanalysis. Hypertension 2010; 55:399–407.eng
dcterms.referencesJamerson K, Weber MA, Bakris GL, Dahlo¨f B, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417–2428.eng
dcterms.referencesYusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al., ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547–1559.eng
dcterms.referencesParving HH, Brenner BM, McMurray JJV, de Zeeuw D, Haffer SM, Solomon SD. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204–2213.eng
dcterms.referencesPatel P, Ordunez P, DiPette D, Escobar MC, Hassell T, Wyss F, et al., Standardized Hypertension Treatment and Prevention Network. Improved blood pressure control to reduce cardiovascular disease morbidity and mortality: the Standardized Hypertension Treatment and Prevention Project. J Clin Hypertens 2016; 18:1284–1294.eng
dcterms.referencesKhatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, et al., PURE study Investigators. Availability and affordability of cardiovascular disease medicines and their effect on use in high income, middle income and low income countries: an Analysis of the PURE Study Data. Lancet 2016; 387:61–69.eng
dcterms.referencesHansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755–1762.eng
dcterms.references[No authors listed]. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317:703–713.eng
dcterms.referencesCushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al., The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575–1585.eng
dcterms.referencesCederholm J, Gudbjornsdottir S, Eliasson B, Zethelius B, Eeg-Olofsson K, Nilsson PM. Blood pressure and risk of cardiovascular disease in type 2 diabetes: further findings from the Swedish National Diabetes Register (NDR-BP-II). J Hypertens 2012; 30:2020–2030.eng
dcterms.referencesThomopoulos C, Parati G, Zanchetti A. Effects of blood-pressurelowering treatment on outcome incidence in hypertension: 10 – Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens 2017; 35:922–944.eng
dcterms.referencesBigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16:1325–1333.eng
dcterms.referencesJensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria and risk of ischemic heart disease. Hypertension 2000; 35:898–903.eng
dcterms.referencesArnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, et al. Lowgrade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112:969–975.eng
dcterms.referencesNinomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20:1813–1821.eng
dcterms.referencesMarso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al., LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Eng J Med 2016; 375:311–322.eng
dcterms.referencesBonadonna RC, Borghi C, Consoli A, Volpe M. Novel antidiabetic drugs and cardiovascular risk: primum non nocere. Nutr Metab Cardiovasc Dis 2016; 26:759–766.eng
dcterms.referencesSon JW, Kim S. Dipeptidyl Peptidase 4 inhibitors and the risk of cardiovascular disease in patients with type 2 diabetes: a tale of three studies. Diabetes Metab J 2015; 39:373–383.eng
dcterms.referencesAbdul-Ghani M, Del Prato S, Chilton R, De Fronzo RS. SGLT-2 inhibitors and cardiovascular risk: lessons learned from the EMPAREG outcome Study. Diabetes Care 2016; 39:715–725.eng
dcterms.referencesVoto L.S. Hipertensión en el embarazo, 1ra Edición 2009, Corpus, ISBN:978-950-9030-69-75.eng
dcterms.referencesGuía para el diagnóstico y tratamiento de la hipertensión en el embarazo, Ministerio de Salud de la Nación Argentina, Segunda edición, 2010–2014.eng
dcterms.referencesPeek M, Shennan A, Halligan A, Lambert PC, Taylor DJ, de Swiet M. Hypertension in pregnancy: which method of blood pressure measurement is most predictive of outcome? Obstet Gynecol 1996; 88:1030–1033.eng
dcterms.referencesFerrazzani S, Caruso A, De Carolis S, Martino IV, Mancuso S. Proteinuria and outcome of 444 pregnancies complicated by hypertension. Am J Obstet Gynecol 1990; 162:366–371.eng
dcterms.referencesWilson ML, Goodwin TM, Pan VL, Ingles SA. Molecular epidemiology of preeclampsia. Obstet Gynecol Surv 2002; 58:39–53.eng
dcterms.referencesAmerican College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122:1122.eng
dcterms.referencesAuthors. WHO recommendations for prevention and treatment of preeclampsia and eclampsia. WHO; 2011; ISBN: 978 92 4 154833 5.eng
dcterms.referencesRedmond N, Baer HJ, Hicks LS. Health behaviors and racial disparity in blood pressure control in the national health and nutrition examination survey. Hypertension 2011; 57:383–389.eng
dcterms.referencesFuchs F. Why do black Americans have higher prevalence of hypertension? An enigma still unsolved. Hypertension 2011; 57:379–380.eng
dcterms.referencesBrewster LLM, Kleijnen J, vanMontfransG. Effect of antihypertensive drugs on mortality, morbidity and blood pressure in blacks. Cochrane Database Syst Rev 2015;CD005183; doi:10.1002/ 14651858.CD005183.pub1.eng
dcterms.referencesEncuesta Demográfica y de Salud Familiar. Instituto Nacional de Estadística e Informática. 2014; Available from: http://proyectos.inei. [Cited 2015].eng


Bloque original
Mostrando 1 - 1 de 1
LASH Guideline Galley Proof.pdf
301.14 KB
Adobe Portable Document Format
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
368 B
Item-specific license agreed upon to submission